Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Johannson, Kerri A; Strâmbu, Irina; Ravaglia, Claudia; Grutters, Jan C; Valenzuela, Claudia; Mogulkoc, Nesrin; Luppi, Fabrizio; Richeldi, Luca; Wells, Athol U; Vancheri, Carlo; Kreuter, Michael; Erice ILD Working Group, (2017). Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? The lancet. Respiratory medicine, 5(7), pp. 591-598. Elsevier 10.1016/S2213-2600(17)30219-9

Full text not available from this repository. (Request a copy)

Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.

Item Type:

Journal Article (Review Article)


04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Mu50 > Forschungsgruppe Pneumologie (Erwachsene)


600 Technology > 610 Medicine & health








Rahel Holderegger

Date Deposited:

29 Nov 2017 09:51

Last Modified:

30 Dec 2017 12:09

Publisher DOI:


PubMed ID:


Additional Information:

Prof. Th. Geiser is a member of the Erice ILD Working Group and mentioned as collaborator


Actions (login required)

Edit item Edit item
Provide Feedback